Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ProACCT

Financiado

Proteomic Analysis of Cell communication in Tumors

Cancer is an enormous biomedical challenge, in part due to the complexity of cancer cell dynamics. The combination of intrinsic genetic alterations and cues from the tumour microenvironment impact the cancer phenotype and create h... ver más

31/07/2027

WEIZMANN

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-04-11

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2021-COG: ERC CONSOLIDATOR GRANTS

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

WEIZMANN

2.00M€ | Lider

Proyectos interesantes

PID2021-122227OB-I00 DISECCIONANDO EL PAPEL DE NPC2 Y CD109, DOS NUEVOS EFECTORES... 182K€ Cerrado

BIO2017-85364-R PREDICCION DE VULNERABILIDADES TERAPEUTICAS EN CANCER POR ME... 242K€ Cerrado

SAF2012-35181 IDENTIFICACION DE MECANISMOS CAUSANTES DE CANCER Y METASTASI... 445K€ Cerrado

SAF2014-60507-JIN IDENTIFICACION DE DETERMINANTES MOLECULARES Y NUEVAS DIANAS... 206K€ Cerrado

EIN2020-112242 DESENTRAÑANDO LA BIOLOGIA DEL CANCER DE VEJIGA MEDIANTE NUEV... 10K€ Cerrado

Tx-phylogeography High throughput phylogeography of tumors: how the tissue en... 2M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 63 meses Fecha Inicio: 2022-04-11
Fecha Fin: 2027-07-31

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Cancer is an enormous biomedical challenge, in part due to the complexity of cancer cell dynamics. The combination of intrinsic genetic alterations and cues from the tumour microenvironment impact the cancer phenotype and create heterogeneous tumours that evolve in space and time. Cancer cells develop distinct phenotypes in diverse tumour regions and different metastatic locations. In addition, cancer progression, metastatic dissemination, and development of therapeutic resistance affect cellular interactions over time. Therefore, understanding tumour dynamics is critical for the development of novel therapeutic approaches. Although tumour heterogeneity has been thoroughly investigated at the genomic and transcriptomic levels, limited studies have investigated heterogeneity at the proteomic level. Changes in protein expression are central determinants of cancer phenotypes; developing a detailed understanding of proteome dynamics would be an enormous scientific advancement in the cancer field. However, technological challenges, and specifically, the challenge of analysing single cells and small groups of cells, have delayed progress along these lines. Here, I propose to combine my cutting-edge clinical proteomic expertise and extensive experience in cancer biology to study the spatial and temporal heterogeneity of cancer at the proteomic level. We will push the boundaries of the technology towards assaying thousands of proteins from single cells and small groups of cells from in-vivo samples. We will combine microfluidic probe technology to map primary tumors and metastases at high spatial resolution, and study mouse models of melanoma and breast cancer to follow temporal changes in metastatic growth and treatment response. This breakthrough in proteomic analysis of cancer dynamics will provide the basis for targeting treatment-resistant metastatic cell populations towards advanced personalized treatment.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores